Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling nasty), or is at least thinking about it. These meds—which include Ozempic, ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...